(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
5 March 2009 (05.03.2009)

PCT

(10) International Publication Number
WO 2009/027644 A3

(51) International Patent Classification:
A61K 9/14 (2006.01) *A61K 31/426* (2006.01)
A61K 9/19 (2006.01) *A61K 45/06* (2006.01)
A61K 9/48 (2006.01) *A61P 35/00* (2006.01)
A61K 31/337 (2006.01)

(21) International Application Number:
PCT/GB2008/002854

(22) International Filing Date:
22 August 2008 (22.08.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0716591.3 24 August 2007 (24.08.2007) GB
60/957,764 24 August 2007 (24.08.2007) US

(71) Applicants *(for all designated States except US)*: **STICHTING HET NEDERLANDS KANKER INSTITUUT** [NL/NL]; Plesmanlaan 121, NL-1066 CX Amsterdam (NL). **SLOTERVAART PARTICIPATIES BV** [NL/NL]; Louwesweg 6, NL-1066 EC Amsterdam (NL).

(71) Applicant *(for LS only)*: **JONES, Nicholas, Andrew** [GB/GB]; Withers & Rogers LLP, Goldings House, 2 Hays Lane, London SE1 2HW (GB).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **BEIJNEN, Jacob, Hendrik** [NL/NL]; Slotervaart Participaties BV, Louwesweg 6, NL-1066 EC Amsterdam (NL). **SCHELLENS, Johannes, Henricus, Matthias** [NL/NL]; Vereniging Het Nederlands Kanker Institut, Plesmanlaan 121, NL-1066 CX Amsterdam (NL). **MOES, Johannes** [NL/NL]; Slotervaart Participaties BV, Louwesweg 6, NL-1066 EC Amsterdam (NL). **NUIJEN, Bastiaan** [NL/NL]; Slotervaart Participaties BV, Louwesweg 6, NL-1066 EC Amsterdam (NL).

(74) Agents: **JONES, Nicholas, Andrew** et al.; Withers & Rogers LLP, Goldings House, 2 Hays Lane, London SE1 2HW (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(88) Date of publication of the international search report:
17 December 2009

(15) Information about Correction:

Previous Correction:
see Notice of 30 April 2009

(54) Title: COMPOSITIONS FOR THE TREATMENT OF NEOPLASTIC DISEASES

(57) Abstract: Pharmaceutical compositions and methods for the treatment of neoplastic disease and comprising the combination of a taxane, such as docetaxel, with a CYP3A4 inhibitor, such as ritonavir. Methods of treatment of neoplastic disease incorporating the administration of a taxane and the administration of a CYP3A4 inhibitor, either simultaneously or separately, are also included. Further, kits for carrying out the methods are included. Solid pharmaceutical taxane compositions for oral administration comprising a substantially amorphous taxane, a carrier and a surfactant are also included.

WO 2009/027644 A3